Replies to post #117540 on NanoViricides Inc. (NNVC)

[Nanotoday]

#1) The R&D element where TheraCour's employees do the drug development and we reimburse TheraCour on a cost + 30% basis. In a prior company, when I used outside people, I paid the contractor who supplied them at cost +30%

Perhaps, but was the contractor the controlling shareholder and decision maker for both companies?

The 30% mark up isn't the issue, it's the guy who benefits from it making the decision to self deal. If Diwan believes in the future success of the 'cides, why would he be taking an additional 30% vig (all profit BTW since NNVC covers all direct costs)?